Search Results for "Heart Failure"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Heart Failure. Results 231 to 240 of 275 total matches.
Alpha-L-Iduronidase (Laronidase; Aldurazyme)
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
and heart disease, and typically die within the
first decade from cardiorespiratory failure. Patients ...
Recombinant human α-L-iduronidase (laronidase; Aldurazyme BioMarin/Genzyme), an orphan drug, has been approved by the FDA for enzyme replacement therapy in mucopolysaccharidosis (MPS) type I, a lysosomal storage disorder caused by deficiency of the enzyme. This review describes the disease, treatment, adverse effects and cost.
Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain
The Medical Letter on Drugs and Therapeutics • May 02, 2011 (Issue 1363)
dysfunction such as anorgasmia.
Small increases in blood pressure and heart rate have
been reported ...
Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral
neuropathic pain and fibromyalgia, duloxetine (Cymbalta – Lilly) has now also been approved for
treatment of chronic musculoskeletal pain.
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
following treatment failure include a longer duration
of treatment with the same therapy, addition ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction
Management of Opioid Withdrawal Symptoms
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
with congestive heart failure,
bradyarrhythmias, or hepatic or renal impairment.
Lofexidine should not be used ...
Pharmacologic management of opioid withdrawal
symptoms can reduce the intensity of drug craving
and improve treatment retention in patients with opioid
use disorder who will receive maintenance treatment.
Withdrawal management without subsequent maintenance
treatment is associated with high rates of
relapse, overdose death, and HIV and/or hepatitis C
virus infection. Several guidelines on management
of opioid withdrawal are available. Maintenance
treatment of opioid use disorder was reviewed in a
previous issue.
Comparison Table: Some Drugs for Plaque Psoriasis (online only)
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
; causal relationship
not established
New onset and exacerbations of heart
failure, pancytopenia ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6 doi:10.58347/tml.2024.1712b | Show Introduction Hide Introduction
Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension
The Medical Letter on Drugs and Therapeutics • Sep 22, 2008 (Issue 1295)
with systolic blood pressure (SBP) 160 mm Hg or
higher, treatment failure (to reduce SBP by 15% or
more ...
Clevidipine (Cleviprex - The Medicines Company), a dihydropyridine calcium channel blocker (CCB), has been approved by the FDA for intravenous (IV) use in lowering high blood pressure. It is the second IV CCB to be marketed in the US; nicardipine has been available in an IV formulation (Cardene IV) for more than 10 years. Like IV nicardipine, clevidipine will probably be used mainly for urgent treatment of hypertension in intensive care units, operating rooms and emergency departments.
Drugs for Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020 (Issue 1596)
or decreased
effective intravascular volume due to diuretic therapy,
cirrhosis, or heart failure increases ...
Many different drugs are used for treatment of
osteoarthritis pain, but none of them prevent
progression of the disease. Nonpharmacologic
approaches including weight management, exercise,
tai chi, physical therapy, assistive devices, and total
joint arthroplasty can also be used. The American
College of Rheumatology (ACR) has published new
guidelines for the management of osteoarthritis of the
hip, hand, and knee.
Prevention and Treatment of Injury from Chemical Warfare Agents
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002 (Issue 1121)
) and depression of CNS respiratory drive. Cardiovascular effects include bradycardia and heart block (muscarinic ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Red Yeast Rice
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
coronary events, including nonfatal MI
and death from coronary heart disease, was 5.7 ...
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
, cirrhosis, or heart failure
increases the risk of NSAID-induced renal toxicity.
Cardiovascular ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.